Double Bond Pharmaceutical International AB (publ) logo

DBP B - Double Bond Pharmaceutical International AB (publ) News Story

SEK1.6 -0.1  -7.0%

Last Trade - 4:22pm

Sector
Healthcare
Size
Micro Cap
Market Cap £6.37m
Enterprise Value £4.94m
Revenue £78.9k
Position in Universe 1671st / 1829

BRIEF-DBP Reports In Vivo Proof-Of-Concept Study Of SI-053 Was Successfully Finished

Oct 16 (Reuters) - Double Bond Pharmaceutical International
AB (publ)  DBPHAb.TE :
    * SI-053 EFFICACY WAS SUCCESSFULLY PROVEN IN IN VIVO STUDY
IN MICE
    * ANIMALS TOLERATED SOC AND SHOWED REDUCED TUMOR VOLUME WHEN
COMPARED TO NON-TREATED ANIMALS
    * EFFECT OF SI-053 WAS POTENTIATED WHEN COMBINED WITH SOC,
RESULTING IN 34% OF TUMOR GROWTH INHIBITION
    * ALL SI-053 DOSES SHOWED STATISTICALLY SIGNIFICANT
SUPERIORITY IN
REDUCING THE TUMOR VOLUME EVEN BEFORE STARTING THE SOC

Source text for Eikon:  ID: 
Further company coverage:  DBPHAb.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.